People Round-Up: Bhadauria Named As Amneal CSO
Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.
You may also be interested in...
Having just sold off relatively small operations in the UK and Germany, Amneal would look for large-scale deals if it were to expand again beyond its US powerbase. The US generics and specialty brands company is also looking to expand its injectables business and is considering a move into biosimilar insulins.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.
Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.